Regeneron priority review for follicular lymphoma candidate

 If approved, odronextamab would be the first and only bispecific antibody approved in both FL and DLBCL – the two most common subtypes of non-Hodgkin lymphoma

European Medicines Agency also reviewing odronextamab Marketing Authorization Application

https://www.biospace.com/article/releases/odronextamab-bla-for-treatment-of-relapsed-refractory-follicular-lymphoma-fl-and-diffuse-large-b-cell-lymphoma-dlbcl-accepted-for-fda-priority-review/